Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Receivables: 2022-2024

Historic Receivables for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Dec 2024 value amounting to $547,000.

  • Amylyx Pharmaceuticals' Receivables fell 87.33% to $232,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 97.94%. This contributed to the annual value of $547,000 for FY2024, which is 98.65% down from last year.
  • According to the latest figures from FY2024, Amylyx Pharmaceuticals' Receivables is $547,000, which was down 98.65% from $40.5 million recorded in FY2023.
  • Over the past 5 years, Amylyx Pharmaceuticals' Receivables peaked at $40.5 million during FY2023, and registered a low of $547,000 during FY2024.
  • In the last 3 years, Amylyx Pharmaceuticals' Receivables had a median value of $15.8 million in 2022 and averaged $19.0 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Receivables soared by 156.55% in 2023 and then tumbled by 98.65% in 2024.
  • Over the past 3 years, Amylyx Pharmaceuticals' Receivables (Yearly) stood at $15.8 million in 2022, then surged by 156.55% to $40.5 million in 2023, then tumbled by 98.65% to $547,000 in 2024.